A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug ...

Alzheimer’s Association urging ‘action now’ for awareness month June is Alzheimer’s and Brain Awareness Month, and the Alzheimer’s Association is urging patients, caregivers, and supporters to “take ...

Cassava will stop developing simufilam for Alzheimer’s this year after a Phase 3 trial failed to improve cognition and daily function.

Kisunla (donanemab-azbt) is an antibody-based therapy approved in the U.S. for adults with early symptomatic Alzheimer’s disease.

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Phospho-Tau 217 (pTau217), a blood-based biomarker test that can help distinguish Alzheimer’s disease ...

Anavex is preparing meetings with regulatory authorities in the U.S., Europe, and Asia-Pacific to discuss Anavex 2-73’s potential approval.

The immunotherapy Leqembi, formerly BAN2401, is now FDA-approved for slowing cognitive decline in patients with Alzheimer's disease.

On-demand treatment with BXCL501 was found to significantly ease episodes of agitation for Alzheimer's patients in a Phase 3 clinical trial.

"Encouraging results" were reported in eight Alzheimer’s patients with dementia who were treated with the experimental therapy COYA 301.

The FDA approved Rexulti (brexpiprazole) as the first therapy in the U.S. for agitation associated with dementia due to Alzheimer’s disease.

Nearly half the Alzheimer's disease patients treated with TrueBinding's investigational therapy TB006 showed cognitive improvement signs.